Health Sciences Assistant Clinical Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Prior to joining the faculty at SSPPS in January 2022, Dr. Kneebusch completed PGY1 Acute Care and PGY2 Psychiatric Pharmacy Residencies at the VA San Diego Healthcare System. Following her completion of residency, she practiced as an inpatient psychiatric pharmacist for 2 years and as a population health behavioral health pharmacist for an Arizona based Medicaid and Medicare insurance provider.
Her research aims to optimize and expand care for patients with psychiatric disorders, including assessing available therapies in treatment and implementation and evaluation of pharmacy practice models for those with comorbid psychiatric diagnoses and substance use disorder. Additionally, she has interests in student and professional wellness and promotion of Diversity, Equity, and Inclusion. Dr. Kneebusch is a Board-Certified Pharmacotherapy Specialist (BCPS) and Board-Certified Psychiatric Pharmacist (BCPP).
Education: B.S. in Biochemistry, California State University, Fullerton (2012); Pharm.D., University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences (2016); PGY1 Acute Care Pharmacy Practice Residency, VA San Diego Healthcare System (2016-2007); PGY2 Psychiatric Pharmacy Residency, VA San Diego Healthcare System (2017- 2018); Board Certified Pharmacotherapy Specialist (2018); Board Certified in Psychiatric Pharmacy (2019).
Awards and Honors: Preceptor Excellence Award – Hospital IPPE (2021); Phi Lambda Sigma Pharmacy Leadership Society (2015)
Leadership Experience: Dr. Kneebusch is an active member of the College of Psychiatric and Neurologic Pharmacists (CPNP); Residency and New Practitioner Committee (2019-2022); Recertification Editorial Board (2022); Board of Pharmacy Specialists BCPP Item Writer (2019, 2022); BCPS Recertification Review Course Field Tester (2020); UCSD SSPPS Admissions Committee Student Member (2013-2016).
- Therapeutics (SPPS 212C)
- Special Topics in Psychiatry Elective (SPPS 286)
- Evaluation of pharmacist interventions in the care of patients with mental illness
- Evaluation of therapy in patients with comorbid psychiatric and substance use disorders
- Butala N, et al. (2021). Impact of a pharmacist-driven tardive dyskinesia screening service. Ment Health Clin. 2021 Jul 16;11(4):248-253.
- Snyder SD, et al. (2021). Use of Intramuscular Chlorpromazine versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Youth. J Pediatr Pharmacol Ther. 26(1):33-41.
- Rowshanrad S, et al. (2016). Medical Management of Sexual Assault Survivors at an Academic Medical Center. Journal of Woman’s Reproductive Health. 1(3):31-37.